X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs DIVIS LABORATORIES - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA DIVIS LABORATORIES GLENMARK PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 20.5 31.9 64.4% View Chart
P/BV x 3.7 5.2 70.9% View Chart
Dividend Yield % 0.3 1.0 34.4%  

Financials

 GLENMARK PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
DIVIS LABORATORIES
Mar-17
GLENMARK PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs9931,222 81.3%   
Low Rs729784 93.0%   
Sales per share (Unadj.) Rs325.5153.1 212.6%  
Earnings per share (Unadj.) Rs39.339.9 98.4%  
Cash flow per share (Unadj.) Rs48.744.6 109.1%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.21.0 23.3%  
Book value per share (Unadj.) Rs159.2201.8 78.9%  
Shares outstanding (eoy) m282.17265.47 106.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.66.6 40.4%   
Avg P/E ratio x21.925.1 87.3%  
P/CF ratio (eoy) x17.722.5 78.7%  
Price / Book Value ratio x5.45.0 108.8%  
Dividend payout %5.125.0 20.3%   
Avg Mkt Cap Rs m242,991266,266 91.3%   
No. of employees `00013.09.7 133.2%   
Total wages/salary Rs m16,4084,687 350.0%   
Avg. sales/employee Rs Th7,083.94,175.0 169.7%   
Avg. wages/employee Rs Th1,265.4481.5 262.8%   
Avg. net profit/employee Rs Th855.11,089.3 78.5%   
INCOME DATA
Net Sales Rs m91,85740,643 226.0%  
Other income Rs m374749 49.9%   
Total revenues Rs m92,23041,392 222.8%   
Gross profit Rs m20,36714,460 140.8%  
Depreciation Rs m2,6441,233 214.4%   
Interest Rs m2,37323 10,500.9%   
Profit before tax Rs m15,72413,953 112.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8273,349 114.3%   
Profit after tax Rs m11,08810,604 104.6%  
Gross profit margin %22.235.6 62.3%  
Effective tax rate %24.324.0 101.4%   
Net profit margin %12.126.1 46.3%  
BALANCE SHEET DATA
Current assets Rs m68,74640,105 171.4%   
Current liabilities Rs m27,0276,595 409.8%   
Net working cap to sales %45.482.5 55.1%  
Current ratio x2.56.1 41.8%  
Inventory Days Days85119 71.7%  
Debtors Days Days9681 118.4%  
Net fixed assets Rs m24,13219,995 120.7%   
Share capital Rs m282531 53.2%   
"Free" reserves Rs m44,64353,043 84.2%   
Net worth Rs m44,92553,574 83.9%   
Long term debt Rs m45,3630-   
Total assets Rs m117,63961,585 191.0%  
Interest coverage x7.6618.4 1.2%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.80.7 118.3%   
Return on assets %11.417.3 66.3%  
Return on equity %24.719.8 124.7%  
Return on capital %19.126.1 73.4%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m56,15235,384 158.7%   
Fx outflow Rs m8,08410,399 77.7%   
Net fx Rs m48,06824,985 192.4%   
CASH FLOW
From Operations Rs m6,57411,493 57.2%  
From Investments Rs m-7,124-11,372 62.6%  
From Financial Activity Rs m5,432-93 -5,834.0%  
Net Cashflow Rs m1,99228 7,015.5%  

Share Holding

Indian Promoters % 48.3 52.0 92.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 11.8 58.5%  
FIIs % 34.4 19.0 181.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.2 61.0%  
Shareholders   56,727 31,796 178.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   AJANTA PHARMA  FDC LTD.  SUN PHARMA  PLETHICO PHARMA  TTK HEALTHCARE  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Energy Stocks Lose(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.4% while the Hang Seng is down 0.5%. The Shanghai Composite is trading up by 0.2%.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 25, 2018 11:15 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS